45 results about "Human proteins" patented technology

Relating to the field of biotechnology, disclosed are a recombinant human elastin peptide with anti-aging effects and a use thereof. The recombinant human elastin peptide comprises an amino acid sequence shown in SEQ ID NO:1 or a fragment of the amino acid sequence shown in SEQ ID NO:1, the fragment comprises 30% or more of SEQ ID NO:1, or a mutant of the amino acid sequence shown in SEQ ID NO:1 or the fragment of the amino acid sequence shown in SEQ ID NO:1. A disclosed method for producing elastin peptides by using a yeast expression system enables the targeted synthesis of highly effective protein fragments with 100% homology to human proteins, while achieving low costs and facilitating large-scale production, avoiding animal-derived sources and viral risks. This makes the recombinant human elastin peptide safe for use as an anti-aging and anti-photoaging active ingredient in cosmetics, while also supporting a use thereof in the field of biomedical materials.

The invention provides a serum-free stem cell culture medium and a preparation method thereof, and the culture medium realizes long-term stable culture of stem cells under a completely serum-free condition by optimizing basic culture medium components and adding a specific growth factor combination, an extracellular matrix simulant and a metabolism regulator. The culture medium comprises a basic culture medium, a recombinant human protein substitute, a cell adhesion promoting factor, a growth factor combination, an antioxidant and a metabolism regulator. Compared with the prior art, the invention has the following advantages: 1) animal-derived components are completely avoided, and the immunogenicity and the difference between batches are reduced; 2) maintaining the dryness of the stem cells through a specific growth factor combination; 3) adding a metabolism regulator to optimize cell energy metabolism; 4) the cost is obviously lower than that of commercially available like products; and 5) supporting long-term culture of stem cells without spontaneous differentiation. The invention also provides a preparation method of the culture medium and a method for culturing stem cells by using the culture medium.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

This invention discloses a functional peptide for increasing recombinant protein yield, the sequence of which is shown in any of SEQ ID No. 1-15. The encoding gene and its applications are also disclosed, along with corresponding methods for increasing protein yield. The functional peptide of this invention can significantly increase the yield of recombinant proteins, significantly reduce the loss rate of recombinant proteins during expression and purification in the MtuΔI-CM protein expression system, reduce the production cost of recombinant proteins, and improve the stability of the target protein. It is suitable for the production of various recombinant human proteins, laying the foundation for large-scale, low-cost mass production of various recombinant proteins and possessing good commercial application prospects.

The present invention provides a method of constructing a library of binder scaffolds (library of protein scaffolds) comprising the steps a) providing an initial polypeptide, wherein said initial polypeptide comprises or consists of a polypeptide having at least 90% identity to SEQ ID NO:1, and b) introducing diversity into copies of said initial polypeptide to form the binder scaffold library (protein scaffold library).

This invention discloses recombinant humanized type III collagen, its preparation method, and its applications, belonging to the field of medical materials technology. The amino acid sequence of this recombinant humanized type III collagen is any one of SEQ ID No. 2-6. Compared to traditional extraction methods, the amino acid sequence of this recombinant protein is highly consistent with that of natural human proteins, completely avoiding the biosafety risks of pathogens, prions, etc., that may exist during animal-derived extraction, while also exhibiting lower immunogenicity. Furthermore, this protein effectively maintains the natural biological activity and stability of collagen. When used as a wound dressing, this material can efficiently promote cell migration, spreading, and proliferation, accelerate tissue regeneration and wound healing, while possessing excellent biocompatibility, controllable degradation, and low immunogenicity.

The invention relates to the technical field of spreading modes of human viruses, in particular to a virus spreading mode prediction model based on interaction of virus protein and human protein, a prediction model construction method and a prediction method. The method specifically comprises the following steps: S1, constructing a training data set of a virus transmission mode; s2, based on the data in the S1, obtaining a virus-human protein interaction prediction result, vectorizing the prediction result by using 0 / 1 coding, and constructing a virus-human protein interaction matrix; and S3, using a machine learning algorithm and a feature selection project to construct and train a virus propagation mode prediction model based on the interaction of the virus protein and the human protein. The method for predicting the virus propagation mode of interaction between the virus protein and the human protein is convenient to use and wide in application range; the method is especially suitable for new viruses or unknown viruses which are not fully researched, and can realize efficient and rapid propagation mode identification.

To provide a modified human protein having improved in vivo stability.SOLUTION: There is provided a modified protein having an amino acid sequence derived from the amino acid sequence of a human wild-type protein, wherein the amino acid sequence of the human wild-type protein is modified to remove one or more ubiquitination sites identified as being present in the amino acid sequence of the human wild-type protein but absent in the homologous non-human animal wild-type protein.SELECTED DRAWING: Figure 1

The invention discloses a method and a device for quantitatively analyzing protein by liquid chromatography-mass spectrometry. The method comprises the following steps: carrying out standardized enzyme digestion treatment on a sample; comparing the theoretical enzyme digestion peptide fragment of the protein drug with the human-derived protein database, and excluding all peptide fragments with consistent sequences to obtain candidate characteristic peptide fragments; a multi-blank matrix experiment verifies that a high-specificity characteristic peptide fragment is screened out; a multi-reaction monitoring mode of an ultra-high performance liquid chromatography-triple quadrupole mass spectrometry combined system is utilized, and the characteristic peptide fragment is used as a quantitative standard substance to establish a quantitative detection method of the protein; and calculating the target protein content through a standard curve prepared based on a matrix. The device integrates a sample pretreatment module, a liquid chromatography-mass spectrometry analysis module and a data processing and control module. The method has the advantages of high specificity, high sensitivity, high stability, high flux and the like, and a complete solution is provided for accurate quantification of trace protein in a complex biological matrix.

A method for identifying cell subpopulations associated with disease phenotypes, belonging to the biomedical field. To identify cell subpopulations associated with disease phenotypes, this invention collects single-cell RNA sequencing data of the disease to obtain a single-cell expression matrix, collects the bulk expression matrix of the disease and corresponding phenotypic tags, and downloads human protein-protein interaction data to construct a protein-protein interaction network; extracts gene signature features of cells and samples and maps them to the protein-protein interaction network to form corresponding cell modules and sample modules; calculates the distance between each cell module and each sample module, and determines a set of multiple sample modules as the sample module set of the disease phenotype; calculates the distance between cell modules and the sample module set of the disease phenotype; creates a background distance distribution to evaluate the statistical significance of the distance between cell modules and the sample module set of the disease phenotype, and identifies cells whose distance to the sample module set of the disease phenotype is significantly smaller than the background distance distribution.

The invention discloses a genetically engineered bacterium for preparing a recombinant III-type human-derived protein, a construction method of the genetically engineered bacterium, the recombinant III-type human-derived protein and a preparation method of the recombinant III-type human-derived protein. The genetically engineered bacterium comprises (1) a first expression vector containing nucleic acid molecules for coding recombinant III-type human-derived protein; and (2) a second expression vector comprising a promoter region fragment of a ptsG gene, a promoter region fragment of an rne gene or a promoter region fragment of a combination thereof. According to the genetically engineered bacterium, the yield of the recombinant III-type human-derived protein is remarkably increased, no adverse effect is caused on growth of the strain, and a simple, convenient and universal optimization strategy is provided for industrial efficient production.

Disclosed herein include methods, compositions, and kits suitable for use in vaccination. Provided are nucleic acid compositions (e.g., mRNA vaccines, DNA vaccines) comprising a polynucleotide encoding a fusion protein. The fusion protein can comprise an antigenic polypeptide (AP) and an endosomal sorting complex required for transport (ESCRT)-recruiting domain (ERD) that is not derived from a human protein. A plurality of fusion proteins can be capable of self-assembling into an enveloped nanoparticle (ENP) secreted from a cell in which the plurality of fusion proteins are expressed. There are also provided populations of ENPs in some embodiments.

An in vitro method of detecting one or more endotoxins of one or more pathogens in a sample, comprising the steps of a. coating a lipid binding protein on a substrate or capturing a lipid binding protein on a capture molecule immobilized on a substrate, b. contacting the lipid binding protein, thus coated or captured, with the sample, c. detecting whether an endotoxin binds to the lipid binding protein, wherein the one or more endotoxins comprise a lipid A moiety and O- polysaccharide moiety, wherein the lipid binding protein is capable of binding the lipid A moiety of an endotoxin, and characterized in that the lipid binding protein is a mammalian protein and preferably is a murine or human protein.

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least two attachment point(s) or conjugation site(s), wherein the molecule further comprises (i) at least two antibody-binding components, preferably at least two hapten units, preferably selected from phosphorylcholine, dinitrophenyl (DNP), galactose-α-1,3-galactose (αGal) and rhamnose (Rha), more preferably at least two rhamnose molecules, covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block and (ii) at least one targeting moiety covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein- based building block. In particular, the at least one protein-based building block comprised in the molecule of the technology: a) comprises at least one conjugation site or attachment point; b) has a molecular mass of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg / mL or more, measured in an aqueous solution at room temperature; and e) does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5x10-4 mol / litre.

The invention provides a network pharmacology-based large model generated traditional Chinese medicine prescription curative effect evaluation method and system, and the method comprises the steps: employing a machine learning model to generate candidate prescriptions, and obtaining all known active components of each traditional Chinese medicine in the prescriptions; predicting human body protein targets corresponding to the patient based on the known active components, and gathering all the human body protein targets to obtain a prescription target set P; obtaining human body protein targets related to the corresponding diseases, and gathering all the human body protein targets corresponding to the diseases to obtain a disease target set D; constructing a protein-protein interaction network; inputting the prescription target point set P and the disease target point set D into a protein-protein interaction network, and constructing a connected sub-network; calculating curative effect indexes of the connected sub-networks; and optimizing the prescription based on the curative effect index to complete the curative effect evaluation of the traditional Chinese medicine prescription. According to the method, calculation and experiments are closely combined, the blindness and the cost of experimental verification are remarkably reduced through a calculation priority strategy, and the research and development efficiency is improved.

Novel compounds capable of blocking viral infections sustained by the SARS-Cov2 virus are provided. A method for preventing and / or treating infectious diseases caused by a virus involving administering the novel compounds is also provided.

The application discloses application of recombinant human USP13 protein in preparation of a drug for treating diabetic cardiomyopathy, and belongs to the technical field of biological medicines.The application first proves that the expression of USP13 in myocardial tissue and serum is significantly reduced under the condition of diabetic cardiomyopathy (DCM); the recombinant human USP13 protein can obviously reduce the level of myocardial cell active oxygen, reduce the expression of NLRP3 inflammasome and active Caspase3 protein in a DCM in-vitro model induced by high sugar / palmitic acid; in a DCM mouse model injected with the recombinant human USP13 protein through a tail vein, myocardial cell apoptosis is inhibited, and the expression of NLRP3 inflammasome and the synthesis of TNF-alpha in the heart of the animal are reduced.USP13 is a human protein, has no obvious toxic side effects, is high in safety, is small in immunological rejection in theory, provides a new effective drug for the clinical treatment of DCM, and has important clinical application value and industrialization prospect.

The disclosure relates to methods of selecting a cancer patient for treatment with an immune checkpoint inhibitor therapy, including assaying a biological sample from a cancer patient for an expression profile of human genes or human proteins encoded by the human genes, wherein the expression profile (i) is identified using a Cross-Species Tumor Immune Microenvironment algorithm, which is based on murine quantitative trait loci (QTL) mapping, and (ii) is associated with immune checkpoint inhibitor response, selecting the cancer patient who has the expression profile for treatment with an immune checkpoint inhibitor therapy, and optionally administering the immune checkpoint inhibitor therapy to the cancer patient.

The disclosure provides agents and methods for preventing or treating diseases associated with one or more antigens. The agents of the invention comprise RNA encoding chimeric proteins comprising an antigenic region. The antigenic region comprises one or more disease-associated antigens, immunogenic variants of fragments thereof. According to the invention, the chimeric proteins, in addition to the antigenic region, comprise a transmembrane domain and cytoplasmatic region, one or both of which are derived from a MHC-I homolog non-native to an organism from which the antigen originates.

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least two attachment point(s) or conjugation site(s), wherein the molecule further comprises (i) at least two antibody-binding components, preferably at least two hapten units, preferably selected from phosphorylcholine, dinitrophenyl (DNP), galactose-α-1,3-galactose (αGal) and rhamnose (Rha), more preferably at least two rhamnose molecules, covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block and (ii) at least one targeting moiety covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein- based building block. In particular, the at least one protein-based building block comprised in the molecule of the technology: a) comprises at least one conjugation site or attachment point; b) has a molecular mass of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg / mL or more, measured in an aqueous solution at room temperature; and e) does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5x10-4 mol / litre.

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least two attachment point(s) or conjugation site(s), wherein the molecule further comprises (i) at least two antibody-binding components, preferably at least two hapten units, preferably selected from phosphorylcholine, dinitrophenyl (DNP), galactose-α-1,3-galactose (αGal) and rhamnose (Rha), more preferably at least two rhamnose molecules, covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block and (ii) at least one targeting moiety covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block.In particular, the at least one protein-based building block comprised in the molecule of the technology:a) comprises at least one conjugation site or attachment point;b) has a molecular mass of 2.5 to 70 kDa;c) has a globular three-dimensional (3D) structure;d) has a solubility of 10 mg / mL or more, measured in an aqueous solution at room temperature; ande) does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5×10−4 mol / litre·ft

The disclosed methods relate to a strategy for producing ground truth quantification ratios (both synthetic knockouts and simulated dose response gradients) using synthetic peptides mixed with a human proteome background. These, synthetic, bespoke proteins serve as a built in quality control for sample preparation for proteomics workflows. Additionally, mixtures of synthetic peptides are combined to form assembled synthetic proteins that can be spiked into samples at the start of processing (e.g., trypsin digesting, purification, etc.). In this way, problems in processing methods can be discovered. Sequences can be engineered to inform how well samples are being processed.

The application discloses a kind of digital signal amplification immunodetection method and system based on surface open magnetic bead array.The method is to construct open surface magnetic bead array on transparent flexible substrate using external magnetic field, while combining reciprocating flow microfluidic technology to accelerate antigen-antibody binding reaction, adopt tyramide signal amplification strategy to realize in situ fluorescence deposition, and combine deep learning-based image recognition algorithm to automatically identify positive magnetic beads, realize quantitative analysis.The method has a significant advantage of high sensitivity and rapid detection with a detection sensitivity of fg / mL order and a detection time of less than 20 minutes.The system includes a magnetic field generation module, a reciprocating flow driving module, an enzymatic signal amplification module, an optical acquisition module and an AI recognition module.It can be used for ultra-sensitive quantitative detection of various human proteins, inflammatory factors, viral antigens and other low-abundance biomarkers.

The invention relates to C. acnes strains carrying DNA vectors for the production of recombinant C. acnes phages. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a template for recombination with C. acnes phage genome leading to the insertion of a gene of interest, for the production of recombinant phages that can lead to the transgene expression into C. acnes infected by the recombinant phage. The invention encompasses, C. acnes strains containing these vectors, C. acnes recombinant phages and methods of using these recombinant phages.

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least two attachment point(s) or conjugation site(s), wherein the molecule further comprises (i) at least two antibody-binding components, preferably at least two hapten units, preferably selected from phosphorylcholine, dinitrophenyl (DNP), galactose-α-1,3-galactose (αGal) and rhamnose (Rha), more preferably at least two rhamnose molecules, covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block and (ii) at least one targeting moiety covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein- based building block. In particular, the at least one protein-based building block comprised in the molecule of the technology: a) comprises at least one conjugation site or attachment point; b) has a molecular mass of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg / mL or more, measured in an aqueous solution at room temperature; and e) does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5x10-4 mol / litre.

The present invention provides a peptide that specifically binds to cells constituting cancer, and a pharmaceutical composition containing the peptide. The present invention is a cancer targeting peptide containing a peptide that binds to cancer cells and that comprises one or more amino acid sequences, each identical to a partial region of a human protein selected from the group consisting of extracellular matrix-constituting proteins, transcriptional regulators, nuclear regulators, signaling pathway proteins, and RNA regulatory proteins. The partial region comprises 5-7 amino acid residues.

To provide a method, a composition and a system for testing a fecal sample containing a small amount of human fecal specimen for a plurality of different marker analytes, for example, a plurality of different human proteins, nucleic acids, and other molecular marker analytes.SOLUTION: There is provided a method for characterizing a human fecal specimen, the method including: (i) providing a dispersed sample containing a small amount of a human fecal specimen dispersed in a predetermined amount of a stabilizing solution; and (ii) analyzing the dispersed sample for various amounts of a plurality of different marker analytes.SELECTED DRAWING: None

The invention relates to the field of molecular biology and biological medicine, and particularly discloses an antithrombotic effect of Meteorin protein or gene. Experiments prove that after Meteorin protein is incubated, the platelet aggregation reaction can be remarkably inhibited, the platelet spreading area can be reduced, blood clot contraction can be delayed, and meanwhile ATP release and alpha particle release of platelets and activation of surface integrin alpha IIb beta 3 can be inhibited. In a whole thrombus experiment, the Meteorin protein can effectively inhibit the formation of arterial thrombosis. The Meteorin protein is a human endogenous protein, so that the Meteorin protein has relatively small side effects, has relatively high safety as a potential drug, and has a good industrialization prospect.

The present invention provides a method of constructing a library of binder scaffolds (library of protein scaffolds) comprising the steps a) providing an initial polypeptide, wherein said initial polypeptide comprises or consists of a polypeptide having at least 90% identity to SEQ ID NO: 1, and b) introducing diversity into copies of said initial polypeptide to form the binder scaffold library (protein scaffold library).